Genomics of ERBB2 -Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab

Marla Lipsyc-Sharf; Esha Jain; Laura C. Collins; Shoshana M. Rosenberg; Kathryn J. Ruddy; Rulla M. Tamimi; Lidia Schapira; Steven E. Come; Jeffrey M. Peppercorn; Virginia F. Borges; Ellen Warner; Craig Snow; Ian E. Krop; Dewey Kim; Jakob Weiss; Jorge Gomez Tejeda Zanudo; Ann H. Partridge; Nikhil Wagle; Adrienne G. Waks

Journal Article

Genomics of ERBB2 -Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab

Lipsyc-Sharf M
Jain E
Collins L
et al.

JCO Precision Oncology (2023) (7)

DOI: 10.1200/po.23.00076

3Citations

2Readers

Get full text

Abstract

In young women with ERBB2+ BC, there was substantial genomic evolution on chemo + H—suggesting resistance pathways.

Cite

CITATION STYLE

APA

Lipsyc-Sharf, M., Jain, E., Collins, L. C., Rosenberg, S. M., Ruddy, K. J., Tamimi, R. M., … Waks, A. G. (2023). Genomics of ERBB2 -Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab. JCO Precision Oncology, (7). https://doi.org/10.1200/po.23.00076

Genomics of ERBB2 -Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab

Abstract

Cite

Register to see more suggestions